Carbamazepine: Medical Uses, Pharmacokinetics and Adverse Effects


Luca Gallelli, PhD (Editor)
Department of Health Science, School of Medicine, University of Catanzaro and Clinical Pharmacology Unit, Mater Domini Hospital, Catanzaro, Italy

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED000000

Carbamazepine (CBZ), one of the most used antiepileptic drugs (AEDs), was introduced on the market in the early 1960’s and ever since, it has become the most frequently prescribed drug for the treatment of several forms of epilepsy. It is also used to treat other pathologies, such as neuropathic pain and psychiatric disorders. This book provides a detailed description of this drug, evaluating all aspects of its pharmacology. CBZ pharmacokinetics is discussed, with a particular emphasis on its metabolism, side effects and drug interactions.

Then the authors focus on its pharmacodynamic effects, and the most recent evidence indicating that CBZ-sodium channel interaction is not specific and ligand-gated ion channels are also affected by the drug. The role of oxacarbazepine, its main metabolite MHD, and other new drugs are explained in detail. Additionally, non-antiepileptic CBZ clinical effects and drug-drug interactions in the elderly under polytherapy are described. In conclusion, the occurrence of carbamazepine in the hydrosphere, its fate and the different technologies available for its remediation are also discussed. (Imprint: Nova Biomedical )



Table of Contents

Chapter 1. Carbamazepine Pharmacokinetic and Drug Interactions in Poly-Treated Patients
(Jawahar Lal, Abhisheak Sharma and Swati Jaiswal, Pharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India, and others)

Chapter 2. Effect of Carbamazepine and Related Compounds on Ligand-Gated Ion Channels: Possible Implications for Synaptic Transmission and Side Effects
(Chiara Di Resta and Andrea Becchetti, Università Vita-Salute San Raffaele, Milano, Italy, and others)

Chapter 3. Carbamazepine and its Derivatives: What’s the Difference?
(Rita Citraro, Serafina Chimirri, Rossana Aiello, Paola Longo and Emilio Russo, Chair of Pharmacology, Science of Health Department, School of Medicine, University of Catanzaro, Catanzaro, Italy)

Chapter 4. Clinical Use of Carbamazepine in Neurological Non-Epileptic Diseases
(Luca Gallelli, Pietro Gareri, Domenico Pirritano, Santo Gratteri, Caterina Palleria, Giovambattista De Sarro and Antonio Siniscalchi,
Chair of Pharmacology, Department of Experimental and Clinical Medicine, School of Medicine, University of Catanzaro, Clinical Pharmacology Unit, Mater Domini University Hospital, Catanzaro, Italy, and others)

Chapter 5. Environmental Fate and Remediation of Carbamazepine in the Hydrosphere
(Moisés Canle López, M. Isabel Fernández, Cristina Martínez and J. Arturo Santaballa, Chemical Reactivity and Photoreactivity Group, Department of Physical Chemistry & Chemical Engineering, Faculty of Sciences, University of A Coruña, Coruña, Spain)


Additional information